Clinical trials
Colorectal Cancer (Locally Advanced or Metastatic) clinical trials
Below are recruiting colorectal cancer (locally advanced or metastatic) clinical trials, each written for real people, not researchers. We’re tracking 5,511 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07711184RecruitingPhase 1
Testing an oral drug for advanced prostate cancer
This study tests a new oral tablet (HRS-7525) for men with advanced prostate cancer that has spread. It aims to see if the drug is safe and effective, and may offer a new treatment option for those who have not responded to standard therapies.
Sydney, New South WalesAges 18–80 - NCT07713550Recruiting
Genetic profiling to guide treatment for advanced solid tumors
This study tests whether analyzing the DNA of your tumor (from a tissue sample or blood draw) can help find the best treatment for your advanced cancer. Researchers will look for genetic changes that could make you eligible for targeted therapy or a clinical trial.
AnderlechtAges 18 years+ - NCT02246634Recruiting
MRI screening to find liver metastases in bowel cancer
This study checks whether a special MRI scan (DW-MRI) can spot liver metastases early in people with high-risk colorectal cancer. Finding metastases sooner may help doctors choose the right treatment path.
Macclesfield, CheshireAges 16 years+ - NCT02222844Recruiting
MRI checks for treatment planning in sigmoid colon cancer
This study uses MRI scans to better plan “curative” treatment (aimed at cure) for sigmoid colon cancer before surgery. It is for people who may still be deciding on the radical (major, curative) treatment plan and who can safely have an MRI.
Huntingdon, CambridgeshireAges 16 years+ - NCT07699705Recruiting
Proton Beam Therapy for Localized Prostate Cancer
This study tests a very short course (ultrahypofractionated) of proton beam radiation for localized prostate cancer. It aims to see if it's safe and effective with fewer treatment visits.
Goyang-si, Gyeonggi-doAges 19 years+ - NCT06650332RecruitingPhase 1/Phase 2
Cadonilimab combo for first-line HER2-positive gastric cancer
This trial tests a new combination treatment (cadonilimab plus chemotherapy) as the first therapy for people with advanced gastric or gastroesophageal junction cancer that has a certain amount of HER2 protein. It aims to see if this combination can shrink tumors and help people live longer.
Hangzhou, ZhejiangAges 18–75 - NCT07692204RecruitingPhase 2
Testing a new drug for advanced stomach cancer
This trial tests a new study drug (SAR445877) for adults with advanced stomach or gastroesophageal junction cancer that has worsened after at least one prior treatment. It aims to find the best dose and see if the drug can help shrink or slow the cancer.
ShanghaiAges 18 years+ - NCT07681882RecruitingPhase 1
Testing DS1025a in people with advanced solid tumors
This trial tests a new drug, DS1025a, for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if it is safe and how well it works.
KashiwaAges 18 years+ - NCT07673029RecruitingPhase 3
Comparing two treatments for HER2-positive breast cancer
This trial compares a new drug, GQ1005, with an existing treatment called T-DM1 for people with HER2-positive breast cancer that has spread or cannot be removed by surgery. The goal is to see which one works better for those who have already received certain other treatments.
Bengbu, AnhuiAges 18–75 - NCT07664579Recruiting
Couples coping together against cancer support program
This trial tests a supportive care program for couples facing cancer. It helps you and your partner work together to manage the challenges of a cancer diagnosis.
Duarte, CaliforniaAges 18 years+ - NCT07657806RecruitingPhase 1
Study of DEC003M for advanced prostate cancer
This trial tests a new targeted therapy (DEC003M) for men with advanced prostate cancer that has spread and stopped responding to standard hormone treatments. It aims to see if this treatment is safe and helps shrink tumors.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07655622RecruitingPhase 1/Phase 2
Vebreltinib and furmonertinib for advanced EGFR-mutant lung cancer with high PD-L1
This trial tests a combination of two targeted drugs, vebreltinib and furmonertinib, for people with advanced non-small cell lung cancer that has an EGFR mutation and high levels of a protein called PD-L1. It may be an option for those who have not yet had treatment for advanced disease.
Nanchang, JianxiAges 18–75 - NCT07656116RecruitingPhase 1
Oncolytic virus therapy for advanced solid tumors
This trial tests a virus-based treatment for people with advanced solid tumors that haven't responded to standard treatments. The virus is designed to infect and kill cancer cells while leaving healthy cells alone.
Langfang, HebeiAges 18 years+ - NCT07660276Enrolling by invitation
AI predicts prostate cancer spread from biopsy
This study uses an artificial intelligence (AI) system to look at prostate biopsy samples and predict if the cancer has spread to the lymph nodes. It may help doctors decide on the best treatment without needing extra surgery or scans.
Changsha, HunanAges 18–90 - NCT06604689Recruiting
AI-guided brain radiation for EGFR-mutant lung cancer with brain mets
This study uses AI to help doctors decide the best way to use brain radiation for people with EGFR-mutant lung cancer that has spread to the brain. It aims to improve treatment planning and outcomes for those already taking a third-generation targeted therapy.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07647328RecruitingPhase 3
Camizestrant and ribociclib for advanced hormone-receptor-positive breast cancer
This trial tests a combination of two drugs (camizestrant and ribociclib) for advanced breast cancer that is hormone-receptor-positive and HER2-negative. The study aims to see if this combination helps patients whose cancer cannot be surgically removed or treated with radiation alone.
Duarte, CaliforniaAges 18–130 - NCT07653893Recruiting
T-DXd for breast cancer that has spread to the brain
This study is looking at how well the drug trastuzumab deruxtecan (Enhertu) works for women and men with HER2-positive breast cancer that has spread to the brain. Researchers want to see how much of the drug gets into the spinal fluid and if it helps shrink brain tumors.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07647016RecruitingPhase 2
New Drug Combination for Advanced Hormone-Receptor-Positive Breast Cancer
This study tests two drugs together—trastuzumab deruxtecan and ivonescimab—for advanced breast cancer that is hormone-receptor-positive but HER2-negative or HER2-low. These drugs work by targeting cancer cells in different ways and may help slow or shrink tumors in patients whose cancer has progressed after earlier treatments.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07649928RecruitingEarly Phase 1
Testing ES502 for Advanced Pancreatic and Other Cancers
This early-stage trial tests a new drug called ES502 for patients with advanced cancers (including pancreatic cancer) that have a specific genetic mutation and certain immune markers. The study aims to find the right dose and see if it helps shrink tumors.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07646171Recruiting
Everolimus After Alpelisib for Advanced Breast Cancer
This trial tests a drug called everolimus in women with hormone receptor-positive metastatic breast cancer who have already tried alpelisib (a PI3K inhibitor) combined with hormone therapy. The goal is to see if this next treatment can help control cancer growth.
Tel AvivAges 21 years+ - NCT07642375Recruiting
Digital Tools to Manage Sarcoma Treatment Side Effects
This study tests whether a digital app or online tool can help you better manage symptoms and side effects from your sarcoma treatment. Researchers want to see if tracking your symptoms online improves how you feel during cancer care.
AthensAges 18 years+ - NCT07641036RecruitingPhase 1/Phase 2
CAR-NK Cell Therapy for Advanced Biliary Tract Cancer
This trial tests a new type of immune cell therapy (CAR-NK cells) designed to target cancer cells in advanced biliary tract cancers—including bile duct and gallbladder cancers. The cells are engineered to recognize and attack cancer cells that have specific markers (HER2 and CEA), and this approach may help patients whose cancer has progressed after standard chemotherapy.
Shenzhen, GuangdongAges 18 years+ - NCT07645261RecruitingPhase 2
Lattice Radiation for Large Tumors When Other Treatments Won't Help
This trial tests a special type of focused radiation therapy (called SBRT-Lattice) for large tumors in patients who can't benefit from surgery, chemotherapy, or standard radiation. The radiation uses a lattice pattern designed to treat the tumor while protecting healthy tissue nearby.
São Paulo, São PauloAges 18 years+ - NCT07644598RecruitingPhase 2
Targeted Radiation Therapy for Low to Intermediate Risk Prostate Cancer
This study tests a new radiation treatment approach that uses MRI imaging to target specific tumor areas within the prostate while reducing radiation to healthy tissue. It may help patients with early-stage prostate cancer get effective treatment with fewer side effects.
Washington D.C., District of ColumbiaAges 18 years+
Hear when a new Colorectal Cancer (Locally Advanced or Metastatic) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for colorectal cancer (locally advanced or metastatic)?
- Yes. Clin2 currently lists 5,511 recruiting colorectal cancer (locally advanced or metastatic) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a colorectal cancer (locally advanced or metastatic) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a colorectal cancer (locally advanced or metastatic) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Locally Advanced or Metastatic Breast Cancer
- Locally Advanced or Metastatic Non-small Cell Lung Cancer
- Locally Advanced Colorectal Cancer
- Lung Cancer (Locally Advanced or Metastatic)
- Liver Cancer (Locally Advanced or Metastatic)
- Metastatic Colorectal Cancer
- Locally Advanced Rectal Cancer
- Metastatic Colorectal Cancer (CRC)
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.